Hologic, Inc. (NASDAQ:HOLX) Stake Boosted by IFM Investors Pty Ltd

IFM Investors Pty Ltd grew its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 12.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 56,081 shares of the medical equipment provider's stock after purchasing an additional 5,996 shares during the quarter. IFM Investors Pty Ltd's holdings in Hologic were worth $3,464,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in HOLX. Smartleaf Asset Management LLC grew its holdings in Hologic by 36.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after buying an additional 159 shares in the last quarter. M&T Bank Corp grew its holdings in Hologic by 4.6% in the 4th quarter. M&T Bank Corp now owns 27,580 shares of the medical equipment provider's stock worth $1,988,000 after buying an additional 1,212 shares in the last quarter. Proficio Capital Partners LLC bought a new position in Hologic in the 4th quarter worth approximately $4,215,000. Raymond James Financial Inc. bought a new position in Hologic in the 4th quarter worth approximately $27,007,000. Finally, PNC Financial Services Group Inc. grew its holdings in Hologic by 5.0% in the 4th quarter. PNC Financial Services Group Inc. now owns 39,014 shares of the medical equipment provider's stock worth $2,813,000 after buying an additional 1,853 shares in the last quarter. 94.73% of the stock is owned by institutional investors.

Insider Activity

In related news, Director Martin D. Madaus purchased 5,445 shares of the firm's stock in a transaction dated Wednesday, May 7th. The stock was bought at an average price of $55.24 per share, for a total transaction of $300,781.80. Following the purchase, the director owned 5,445 shares in the company, valued at $300,781.80. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 1.88% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Royal Bank Of Canada cut their target price on Hologic from $75.00 to $70.00 and set a "sector perform" rating for the company in a research report on Friday, May 2nd. Stephens cut their target price on Hologic from $77.00 to $70.00 and set an "overweight" rating for the company in a research report on Tuesday, May 13th. Evercore ISI cut their target price on Hologic from $65.00 to $62.00 and set an "in-line" rating for the company in a research report on Friday, May 2nd. Raymond James Financial restated an "outperform" rating and issued a $71.00 target price (down from $90.00) on shares of Hologic in a research report on Friday, May 2nd. Finally, Wall Street Zen downgraded Hologic from a "buy" rating to a "hold" rating in a research report on Monday, May 5th. Twelve research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Hologic presently has a consensus rating of "Hold" and an average price target of $77.42.

Hologic Stock Performance

Shares of NASDAQ HOLX opened at $64.37 on Tuesday. The company has a debt-to-equity ratio of 0.54, a current ratio of 3.24 and a quick ratio of 2.52. Hologic, Inc. has a one year low of $51.90 and a one year high of $84.67. The business's 50-day moving average price is $60.84 and its two-hundred day moving average price is $63.60. The company has a market capitalization of $14.34 billion, a P/E ratio of 27.16, a price-to-earnings-growth ratio of 2.37 and a beta of 0.55.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.71% and a net margin of 13.83%. The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1 billion. During the same period in the prior year, the firm posted $1.03 EPS. The business's revenue was down 1.2% compared to the same quarter last year. Analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.